sign in · help · news · about ·

BibSonomy :: user :: kanefendt ::

tag user group author concept BibTeX key search:all search:kanefendt

The blue social bookmark and publication sharing system.

>
|
<

bookmarks

bookmarks per page: 5 10 20 50 100

RSS BibTeX RDF more

publications

(40)

<< < 1 | 2 > >>

Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization
D. Fukumura, and R. K. Jain Microvasc.Res. 74(2-3):72-84 (2007)
to & Angiogenesis Animals Blood Endothelial Factors Growth Humans Inhibitors Laboratories Neoplasms Neovascularization Pathologic Research Vascular Vessels antagonists blood cells drug inhibitors pathology supply therapeutic therapy use by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib
T. F. Chu, M. A. Rupnick, R. Kerkela, S. M. Dallabrida, D. Zurakowski, L. Nguyen, K. Woulfe, E. Pravda, F. Cassiola, J. Desai, S. George, J. A. Morgan, D. M. Harris, N. S. Ismail, J. H. Chen, F. J. Schoen, A. D. van den Abbeele, G. D. Demetri, T. Force, and M. H. Chen Lancet 370(9604):2011-2019 (2007)
to & Aged Agents Animals Antineoplastic Arteries Artery Blood Carcinoma Coronary Disease Failure Female Gastrointestinal Heart Humans Hypertension Indoles Kinase Kinases Male Mice Middle Multicenter Pressure Protein-Tyrosine Pyrroles Rats Research Retrospective Safety Stroke Stromal Studies Topic Tumors Tyrosine Volume adverse antagonists as blood chemically drug effects induced inhibitors methods therapeutic therapy toxicity use by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
The biology of epidermal growth factor receptor and its value as a prognostic/predictive factor
A. P. Dei Tos Int.J.Biol.Markers 22(1 Suppl 4):S3-S9 (2007)
to Antibodies Biological Epidermal Expression Factor Gene Growth Human Humans Immunohistochemistry Markers Monoclonal Neoplasms Neoplastic Prognosis Receptor Regulation Tyrosine analysis drug effects etiology identify pathology physiology response therapeutic therapy use by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Surrogate biomarkers in evaluating response to anti-angiogenic agents: focus on sunitinib
S. E. Deprimo, and C. Bello Ann.Oncol (2007)
to Angiogenesis Biological Cells Endothelial Growth Humans Indoles Inhibitors Laboratories Markers Neoplasms Neovascularization Pathologic Proteins Pyrroles Research Tumor blood cells diagnosis drug effects metabolism methods pathology pharmacology protein response supply therapeutic therapy use by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Molecular and cellular biomarkers for angiogenesis in clinical oncology
F. Bertolini, P. Mancuso, Y. Shaked, and R. S. Kerbel Drug Discov.Today 12(19-20):806-812 (2007)
to Angiogenesis Antigens Biological Cells Endothelial Humans Inhibitors Markers Microcirculation Neoplasms Neovascularization Pathologic Research Tumor blood cells diagnosis drug metabolism pathology pharmacology supply therapeutic therapy use by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Surrogate predictive biomarkers for response to anti-EGFR agents: state of the art and challenges
F. Cappuzzo, L. Toschi, G. Finocchiaro, C. Ligorio, and A. Santoro Int.J.Biol.Markers 22(1 Suppl 4):S10-S23 (2007)
to & Antibodies Biological Carcinoma Dosage Drug Epidermal Factor Gene Growth Human Humans Immunohistochemistry Inhibitors Kinase Kinases Lung Markers Monoclonal Mutation Neoplasm Neoplasms Non-Small-Cell Phosphoproteins Predictive Protein Protein-Tyrosine Proteins Proto-Oncogene Quinazolines Receptor Resistance Tests Tyrosine Value analysis antagonists c-akt drug effects erbB-2 erbB-3 genetics identify inhibitors of protein response therapeutic therapy use by kanefendt and 1 other user on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Angiogenesis: an organizing principle for drug discovery?
J. Folkman Nat.Rev.Drug Discov. 6(4):273-286 (2007)
to Agents Angiogenesis Animals Antineoplastic Blood Endothelium Humans Inhibitors Neoplasms Neovascularization Pathologic Physiologic Platelets RANGE Research drug effects genetics pathology pharmacology physiology therapeutic therapy use by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Molecular basis for sunitinib efficacy and future clinical development
S. Faivre, G. Demetri, W. Sargent, and E. Raymond Nat.Rev.Drug Discov. 6(9):734-745 (2007)
to & A Angiogenesis Animals Carcinoma Clinical Design Drug Endothelial Factor France Growth Humans Indoles Inhibitors Kinase Kinases Neoplasm Neoplasms Protein-Tyrosine Pyrroles Receptors Resistance Topic Trials Tyrosine Vascular adverse antagonists as biosynthesis blood drug effects enzymology inhibitors metabolism pharmacology response supply therapeutic therapy use by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Molecular regulation of tumor angiogenesis: mechanisms and therapeutic implications
J. Harper, and M. A. Moses EXS (2006)
to & Angiogenesis Capillaries Human Humans Inhibitors Neoplasms Neovascularization Pathologic Research blood control drug metabolism pathology pharmacology prevention supply therapeutic therapy use by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions
A. Morabito, Maio E. De, Maio M. Di, N. Normanno, and F. Perrone Oncologist. 11(7):753-764 (2006)
to & A Angiogenesis Clinical Endothelial Factor Growth Human Humans Inhibitors Kinase Kinases Lung Neoplasms Piperidines Protein Protein-Tyrosine Proteins Quinazolines Receptors Research Safety Topic Trials Tyrosine Vascular antagonists as drug inhibitors metabolism protein therapeutic therapy use by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Effects of aspirin on intra-platelet vascular endothelial growth factor, angiopoietin-1, and p-selectin levels in hypertensive patients
S. Nadar, A. D. Blann, and G. Y. Lip Am.J.Hypertens. 19(9):970-977 (2006)
to A Activation Aged Aggregation Angiopoietin-1 Aspirin Biological Blood Case-Control Count Cyclooxygenase Endothelial England Factor Female Follow-Up Growth Humans Hypertension Immunoassay Inhibitors Longitudinal Male Markers Middle Outcome P-Selectin Platelet Platelets Pressure Research Studies Thrombosis Treatment Vascular blood drug effects metabolism methods pharmacology physiopathology therapeutic therapy use by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan
B. Vincenzi, D. Santini, A. Russo, M. Gavasci, F. Battistoni, G. Dicuonzo, L. Rocci, V. M. Rosaria, N. Gebbia, and G. Tonini Pharmacogenomics. 8(4):319-327 (2007)
to & A Adult Aged Antibodies Antineoplastic Biological Camptothecin Chemotherapy Colorectal Combined Disease Endothelial Factor Female Growth Humans Male Markers Medical Middle Monoclonal Neoplasms Oncology Outcome Progression Prospective Protocols Rate Studies Survival Treatment Tumor Vascular administration analogs antagonists blood derivatives dosage drug inhibitors methods mortality response therapeutic therapy trends use by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Doxycycline reduces plasma VEGF-C/sVEGFR-3 and improves pathology in lymphatic filariasis
A. Y. Debrah, S. Mand, S. Specht, Y. Marfo-Debrekyei, L. Batsa, K. Pfarr, J. Larbi, B. Lawson, M. Taylor, O. Adjei, and A. Hoerauf PLoS.Pathog. 2(9):e92 (2006)
to & Adult Aged Animals C Data Doxycycline Elephantiasis Endothelial Factor Female Filarial Filaricides Growth Humans Hydrocele Intercellular Lymphatic Lymphedema Male Microfilaria Middle Molecular Outcome Parasitemia Peptides Plasma Proteins Receptor-3 Research Sequence Signaling System Testicular Testis Treatment Vascular Vessels Wolbachia and antagonists blood drug effects immunology inhibitors isolation parasitology pathology physiology protein purification therapeutic therapy ultrasonography use by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Monoclonal antibodies against epidermal growth factor receptor in advanced colorectal carcinoma: clinical efficacy and markers of sensitivity
E. Carcereny, and J. Maurel Rev.Recent Clin.Trials 1(2):113-118 (2006)
to & Animals Antibodies Biomarkers Carcinoma Colorectal Drug Epidermal Europe Factor Factors Growth Humans Immunologic Ligands Medical Monoclonal Mutation Neoplasm Neoplasms Oncology Pharmacological Phosphorylation Prognosis Receptor Resistance Tyrosine antagonists genetics inhibitors pharmacology response therapeutic therapy use by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Biomarker method validation in anticancer drug development
J. Cummings, T. H. Ward, A. Greystoke, M. Ranson, and C. Dive Br.J.Pharmacol. 153(4):646-656 (2008)
to & Adherence Agents Animals Antineoplastic Assay Biomarkers Cell Clinical Control Death Drug Enzyme-Linked Europe Evaluation Guideline Guidelines Humans Immunosorbent Keratin-18 Laboratories Mass Pharmacological Preclinical Proteins Quality Reproducibility Research Results Spectrometry Terminology Topic Trials analysis as drug effects jurisprudence legislation methods of pharmacology protein standards therapeutic use by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane
H. J. Burstein, A. D. Elias, H. S. Rugo, M. A. Cobleigh, A. C. Wolff, P. D. Eisenberg, M. Lehman, B. J. Adams, C. L. Bello, S. E. Deprimo, C. M. Baum, and K. D. Miller J Clin Oncol 26(11):1810-1816 (2008)
to & Administration Adult Aged Agents Anthracyclines Antineoplastic Biological Breast Bridged Carcinoma Chemotherapy Combined Compounds Diseases Drug Fatigue Female Gastrointestinal Growth Hematologic Humans Indoles Inflammation Kinase Kinases Markers Middle Neoplasms Oral Plasma Protein-Tyrosine Protocols Pyrroles Rate Schedule Survival Taxoids Tumor Tyrosine administration adverse analysis antagonists blood chemically classification dosage drug effects induced inhibitors methods mortality response secondary therapeutic therapy use by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
EGFR FISH versus mutation: different tests, different end-points
F. Cappuzzo Lung Cancer 60(2):160-165 (2008)
to & Analysis Carcinoma Clinical DNA Drug Epidermal Factor Fluorescence Growth Humans Hybridization In Inhibitors Kinase Lung Mutation Mutational Neoplasm Neoplasms Non-Small-Cell Patient Population Protein Receptor Resistance Selection Situ Topic Trials Tyrosine analysis antagonists as drug genetics identify inhibitors protein response therapeutic therapy use by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
How well do angiogenesis inhibitors work? Biomarkers of response prove elusive
V. Brower J.Natl.Cancer Inst. 101(12):846-847 (2009)
to A Analysis Angiogenesis Animals Antibodies Benzenesulfonates Biological Cells Cytokines Disease-Free Endothelial Factor Growth Humans Indoles Inhibitors Markers Monoclonal Neoplasms Pyridines Pyrroles Survival Tumor Vascular blood drug effects metabolism mortality pathology pharmacology response supply therapeutic therapy use by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors
F. A. Eskens, N. Steeghs, J. Verweij, J. L. Bloem, O. Christensen, Doorn L. van, J. Ouwerkerk, M. J. Jonge, J. W. Nortier, J. Kraetzschmar, P. Rajagopalan, and H. Gelderblom J.Clin.Oncol. 27(25):4169-4176 (2009)
to & A Administration Adolescent Adult Aged Angiogenesis Biological Contrast Dose Dose-Response Drug Endothelial Factor Factors Fatigue Female Growth Human Humans Hypertension Imaging Inhibitors Kinase Magnetic Male Markers Maximum Media Medical Metastasis Middle Neoplasm Neoplasms Oncology Oral Outcome Pharmacokinetics Plasma Platelet-Derived Protein Proteins Proto-Oncogene Pyridazines Pyridines Receptor Receptor-2 Receptor-3 Relationship Research Resonance Safety Schedule Time Tolerated Treatment Tumor Tyrosine Vascular Young administration adverse antagonists beta blood c-kit diagnostic dosage drug effects enzymology inhibitors methods pathology protein response supply therapy toxicity use by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Antiangiogenesis research is booming, as questions and studies proliferate
V. Brower J.Natl.Cancer Inst. 101(11):780-781 (2009)
to & Administration Analysis Angiogenesis Antibodies Antineoplastic Biological Chemotherapy Colorectal Combined Controlled Drug Humans Inhibitors Markers Monoclonal Neoplasms Pericytes Protocols Randomized Research Schedule Survival Topic Trials Tumor administration analysis as blood dosage drug effects mortality supply therapeutic therapy use by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)

<< < 1 | 2 > >>publications per page: 5 10 20 50 100

a gripper